NEW YORK, Sept. 2, 2015 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Northern District of California on behalf of investors who purchased Avalanche Biotechnologies, Inc. (NASDAQ: AAVL) securities pursuant and/or traceable to the Company's Initial Public Offering on or about July 31, 2014 and/or between July 31, 2014 and June 15, 2015.
Click here to learn about the case: http://docs.wongesq.com/AAVL-Info-Request-Form-847. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period defendants issued materially false and misleading statements and/or failed to disclose that Phase 2a of the study for its drug AVA-101 was not designed to show any statistical significance between the active and control groups in the secondary endpoints.
If you suffered a loss in Avalanche you have until September 8, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/AAVL-Info-Request-Form-847.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.